Jay R. Luly insider trades

Open-market stock purchases and sales by Jay R. Luly, President and CEO at Enanta Pharmaceuticals Inc, from SEC Form 4 filings since Dec 5, 2013.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +98%.

Recent trades

DateStockTradeValue
Feb 12, 2026ENTA Enanta Pharmaceuticals IncBought (not open market)—
Feb 12, 2026ENTA Enanta Pharmaceuticals IncBought (not open market)—
Feb 12, 2026ENTA Enanta Pharmaceuticals IncSold (not open market)$87.7K
Dec 5, 2025ENTA Enanta Pharmaceuticals IncSold$67.5K
Dec 1, 2025ENTA Enanta Pharmaceuticals IncSold (not open market)$26.6K
Nov 25, 2025ENTA Enanta Pharmaceuticals IncBought (not open market)—

Companies traded

  • ENTA Enanta Pharmaceuticals Inc: 1 buy, 38 sales, last Feb 12, 2026

Get free alerts when Jay R. Luly files a new trade →